Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.
|
| Abstract |
CD99 is a 32kDa surface glycoprotein that is involved in the migration of leukocytes, cell-cell adhesion and apoptosis of T cells and Ewing's sarcoma (ES) cells, two cell types with a high level of CD99 expression. Engagement of the molecule induces a rapid death signal that appears to be related to the level of expression of this antigen. The rapid apoptosis induced by agonistic anti-CD99 monoclonal antibodies is of clinical interest in ES, a tumour for which no new drugs have been described as clearly effective in the last 10 years. In this study, we show that an anti-CD99 monoclonal antibody can be used to advantage in association with doxorubicin. Striking effectiveness was observed against local tumours and metastases. No remarkably toxic effects of anti-CD99 monoclonal antibody were found in bone marrow against blood precursors. These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES.
|
|---|---|
| Authors | Katia Scotlandi, Stefania Perdichizzi, Ghislaine Bernard, Giordano Nicoletti, Patrizia Nanni, Pier-Luigi Lollini, Antonio Curti, Maria Cristina Manara, Stefania Benini, Alain Bernard, Piero Picci |
| Journal | European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 42 Issue 1 Pg. 91-6 (Jan 2006) ISSN: 0959-8049 [Print] England |
| PMID | 16326096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!